Full-Time
Clinical Account Specialist HS-Manhattan North
UCB Pharma
10,001+ employees
Biopharmaceuticals for neurology and immunology therapies
Compensation Overview
$132k - $174k/yr
New York, NY, USA
Hybrid
Hybrid role; 40% of time in the office in New York, New York.
 Sales & Account Management (1) |
|---|
Get referred to UCB Pharma
See people who can refer or advise you
- Bachelor’s Degree BA/BS
- Minimum of 3 years of direct selling experience to healthcare professionals in the pharmaceutical, biotech, device or healthcare industry
- Must have a valid Driver License with no more than 2 moving violations in the previous three-year period
- Must reside within assigned geography
- Owning responsibility for attaining territory sales goals and objectives through effective territory planning, visiting clinical decision makers with appropriate reach/frequency, collaborating with the Immunology Clinical Specialist and other members of the UCB Patient Value Team.
- Analyzing territory data to build and adapt a customer call plan to establish professional working relationships with HCP and support staff.
- Maintaining a thorough understanding of the competitive marketplace and drivers of prescriber decisions.
- Conducting account related activities such as profiling, call planning, and reviewing UCB sales data with assigned stakeholders.
- Making strategic business decisions in the management of allocated resources such as financial/budgets, samples, access opportunities.
- Coordinating and supporting promotional educational opportunities and programs intended to expand the knowledge of medical stakeholders and staff (e.g., peer-to-peer educational opportunities) in accordance with UCB policy.
- 5 years of direct selling experience to healthcare professionals in the pharmaceutical, biotech, device or healthcare industry
- Experience calling on Dermatologists in the assigned geography
- Experience selling injectable biologics products
- Proven track record of success in Pharmaceutical Sales demonstrated by goal attainment and awards achievement (President’s Club, etc.)
- Biologic product launch experience
- Demonstrated business and strategic planning skills to identify unique selling opportunities and adaptability to changing market conditions
- Demonstrated understanding of managed care landscape and how it influences/impacts business
- Strong verbal, influencing, presentation and written communication skills
- Strong collaboration skills and success working in teams
UCB Pharma focuses on developing treatments for severe diseases in neurology and immunology. It discovers, develops, and commercializes novel molecules and generates products aimed at improving patient lives. The company works by researching and developing therapies, integrating patient insights to guide innovation, and investing over a quarter of revenue into scientific research. Its global presence (about 9,000 employees across 40 countries) and €5.3 billion 2023 revenue reflect its scale and commitment to bringing therapies to patients worldwide. UCB differentiates itself by combining direct patient engagement with substantial R&D investment to address unmet needs in neurology and immunology, aiming to transform lives through science and patient care.
Company Size
10,001+
Company Stage
IPO
Headquarters
City of Brussels, Belgium
Founded
1928
Get referred to UCB Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Bimzelx growth provides commercial momentum for immunology expansion.
- The 2026 Georgia manufacturing investment supports future U.S. biologics capacity.
- Specialty-disease focus creates demand for biomarker, translational, and reimbursement tools.
What critics are saying
- Bimzelx concentration exposes growth to pricing, safety, or differentiation setbacks.
- Legacy epilepsy brands face ongoing erosion from loss of exclusivity and competition.
- Specialist reimbursement pressure can restrict access across UCB's high-cost franchises.
What makes UCB Pharma unique
- UCB centers research on neurology and immunology, with patient-input programs guiding development.
- The company reinvests over 25% of revenue into scientific research.
- UCB pursues disease modification, cure, and differentiated molecules across multiple modalities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Paid Vacation
PTO/vacation
Paid Sick Leave
Paid Holidays
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Conference Attendance Budget
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Home Office Stipend
Phone/Internet Stipend
Professional Development Budget
Stock Options
Company Equity
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 7%3 questions to adrian cuadra leon, general manager of UCB ALPS (austria & Switzerland). A part of your work focuses on rare diseases. In this field in particular, rapid access to innovative therapies is crucial. In your view, what role does patient access play in Switzerland's attractiveness as a pharmaceutical hub? Switzerland has built a strong reputation based on scientific excellence, a highly developed healthcare system, and a culture of innovation. But today, the real differentiator is not only the ability to discover new therapies, but it is also the ability to ensure that patients benefit from them quickly and predictably. When innovative medicines reach patients efficiently, it reinforces Switzerland's position as a country where innovation is fully realized. It also influences key decisions for companies: where to invest, where to conduct clinical trials, and where to scale new therapies across different therapeutic areas. Conversely, when access becomes slower or less predictable, there is a risk that innovation gradually shifts toward countries that are more agile. In today's global environment, this is not a theoretical risk, competition between countries to attract research, development, and launches is intensifying. Switzerland continues to have all the strengths to remain at the forefront but sustaining this leadership will require maintaining alignment between scientific progress and access frameworks ensuring that evaluation, pricing, and reimbursement processes reflect the speed and complexity of modern innovation. Patient access is part of UCB sustainability ambition and is a defining factor of a country's attractiveness as a pharmaceutical and innovation hub. It goes beyond healthcare performance as it reflects how effectively a system translates scientific progress into real-world outcomes for patients across all disease areas, from broad to rare conditions. Not all patients or populations experience disease or access to care in the same way. By continuously deepening its understanding of patients through richer data and insights, Interpharma can better inform its research and development until distribution and delivery. In this way, Interpharma strive to remove barriers to access, such as limited awareness, availability, affordability, accessibility and adoptability, so that patients who can benefit from new medicines are able to access them. You have worked in various European markets. Based on your international experience, how attractive is Switzerland as a location for innovative pharmaceutical companies? Having worked across several European markets, I can say that Switzerland remains an attractive location for innovative pharmaceutical companies, but it is increasingly competing in a more dynamic and demanding global environment. Switzerland has its own independent regulatory authority, which allows for high-quality and science-driven assessments. Combined with a strong and well-funded healthcare system, this creates a very solid foundation for innovation. Another key strength is the quality of collaboration between stakeholders, industry, academia, healthcare providers, and authorities. This spirit of partnership has historically been a major enabler of innovation and trust, and it remains one of Switzerland's defining advantages. At the same time, Interpharma need to be vigilant as over the years, Switzerland has gradually lost positions in international comparisons on patient access to innovative therapies. This is often linked to the fact that, while its system is rigorous, it can also be slower in enabling access and sometimes more restrictive in defining eligible patient populations. In a global environment where other countries are moving with speed and ambition to attract investment and accelerate access, this becomes a critical factor. Competitiveness today is not only about scientific excellence, but also about how quickly innovation can reach patients in practice. Switzerland is still well positioned but sustaining its attractiveness will require ensuring that collaboration remains at the center, and that the system continues to evolve, particularly in access timelines, regulatory efficiency, recognition of innovation and decision-making agility. The Life Sciences industry is a major contributor of economic growth in Switzerland. Taking the example of UCB, since 1996, the company has invested more than 750 million Swiss francs in its Bulle site (canton of Fribourg). According to the study carried out in 2024 by BAK Economics, life sciences is a major industry in the Fribourg economy, generating an added value of more than one and a half billion francs in 2023, this makes it the most productive branch of the canton of Fribourg. In October 2025, UCB announced that it will make an additional investment of more than 100 million CHF in the Bulle site for a new chemical compound manufacturing unit. By 2029-2030 UCB plans to create about 80 new jobs in Switzerland in addition to the already more than 800 employees. The UCB example is a testament to Switzerland's attractiveness for innovation and investment. However, maintaining this momentum will require policies that evolve at the same pace as science and global competition. The risk is that Switzerland could progressively lose momentum if it does not adapt with the same speed as the global innovation landscape. Other countries are already moving decisively to position innovation as a core enabler of health outcomes and system sustainability, not simply as a cost. For Switzerland, the urgency is in the need to continue evolving its frameworks to ensure that innovation is recognized not only for its budget impact, but for the value it brings to patients, to society, and to the healthcare system. With courageous decisions, Switzerland has the opportunity to reinforce its position as a global benchmark, combining scientific excellence with a clear commitment to delivering meaningful impact for patients. The development of new therapies, particularly in fields such as neurology and rare diseases, requires close collaboration between different stakeholders. What role does policy play in this collaboration, and how do you plan to strengthen it further as an Interpharma member? Innovation in areas such as neurology, immunology, and rare diseases is, by nature, highly complex. It requires close alignment between multiple stakeholders: industry, academia, healthcare professionals, regulators, payers, and people living with these conditions. Policy plays a critical role in enabling this ecosystem to function effectively. Policy can do more than regulate; it creates the conditions for trust, collaboration, and speed. It shapes how Interpharma generate evidence, how Interpharma use data, how Interpharma conduct research, and ultimately how quickly patients can benefit from innovation. In that sense, policy is a strategic enabler of progress. Switzerland has strong foundations in this regard. There is a long tradition of constructive dialogue and partnership across stakeholders, which has supported high-quality research and innovation. But as science evolves and is becoming more personalized, more data-driven, and more complex, policy frameworks must evolve as well. Looking ahead, there are three areas where policy can further strengthen collaboration: * First, enabling faster and more integrated access to innovation. This requires continued alignment between regulatory approval, pricing, and reimbursement processes, with a shared focus on delivering value to patients quickly and predictably. * Second, unlocking the potential of data and digital health. Switzerland has tremendous assets, but greater clarity and connectivity are needed to fully leverage real-world evidence and support better, faster decision-making. * Third, reinforcing Switzerland's attractiveness for clinical research. Simplifying processes and reducing administrative complexity, while maintaining high standards, will be key to ensuring Switzerland remains a preferred location for innovation. As an Interpharma member, I see its role as an active and responsible partner in this evolution. That means engaging in open, solution-oriented dialogue, bringing evidence and international perspective, and contributing to a shared ambition: making Switzerland not only a place where innovation is discovered, but where it is effectively translated into better outcomes for people. At UCB, Interpharma is committed to ensuring that innovation reaches the people who need it most. Through close collaboration with authorities, healthcare providers, patient organizations, and payers, Interpharma work every day to help accelerate access to innovative medicines while supporting a sustainable healthcare system. This commitment reflects its broader belief that scientific innovation only achieves its full value when it translates into better outcomes for people. Ultimately, if Interpharma align around a common vision, Switzerland can continue to lead, not only through scientific excellence, but through its ability to collaborate, adapt, and deliver meaningful impact for patients and the society.
Neurona Therapeutics, cell therapy company focused on the development of breakthrough treatments for neurological disorders. Here you'll find information about their funding, investors and team.
UCB investing $2B to build manufacturing facility in Georgia. March 25, 2026 | The belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB's first biologics manufacturing facility in the U.S. UCB is investing $2 billion to build its first biologics manufacturing facility in the U.S., putting down roots in Georgia to support products including the psoriasis drug Bimzelx. Belgium-based UCB unveiled plans to build a biologics manufacturing facility in the U.S. last year. At that time, the drugmaker was undertaking a feasibility study to determine the ideal U.S. location. UCB said it was prioritizing regions with strong talent pipelines, an essential consideration for a company seeking to hire at a time when many businesses are preparing to staff new U.S. production sites. UCB has chosen Gwinnett County, Georgia, on the outskirts of Atlanta as the location of its manufacturing facility, the state's governor announced Tuesday. The company plans to build a 460,000-square-foot plant in the county. UCB's facility will create about 330 permanent manufacturing jobs, plus more than 1,000 construction roles, and will use advanced manufacturing technologies including AI, robotics and automation, the company said. The company is the first global tenant at a 2,000-acre campus that is under construction in Rowen. Officials at the Rowen development said they expect design and construction to take six to seven years. The UCB project follows years of public investment in infrastructure such as water and sewer capacity to get the site ready to host companies. Two new developments for lab and office space are expected to add over 2,000 acres of space in Atlanta to accommodate the life science industry's rapid growth. May 16, 2023 Gwinnett County has committed more than $174 million in incentives such as property tax savings, fee waivers and infrastructure investment to support the project. Georgia Governor Brian Kemp said a team traveled to Belgium to pitch to UCB leaders earlier this year. The efforts have secured the largest capital investment in Gwinnett County's history. UCB's new manufacturing location is about 40 miles from its U.S. headquarters, which is northwest of Atlanta in the city of Smyrna. The presence of the University of Georgia, Emory University, Spelman, Georgia Gwinnett College and Georgia Tech in the region could give UCB the talent pipeline it prioritized in its search for a U.S. manufacturing base. The investment follows calls by the Trump administration for biopharma companies to make medicines in the U.S. UCB also faces pressures to meet demand for Bimzelx, an IL-17A/IL-17F blocker that the FDA approved for use in plaque psoriasis in 2023. U.S. Bimzelx sales increased almost sixfold last year, jumping to almost 1.7 billion euros ($2 billion) to make the autoimmune drug the company's best-selling product. Speaking on an earnings call last month, UCB CEO Jean-Christophe Tellier said the U.S. manufacturing investment will support Bimzelx production. UCB has also scaled up partnerships with contract manufacturers in the U.S.
Georgia trend daily - March 25, 2026. 7 hours ago Staff reports, Gov. Kemp on Tuesday announced that global biopharmaceutical giant UCB, Inc. is planning a significant investment of $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation's state-of-the-art, 2,000-acre science and learning campus in Gwinnett County. Loran Smith writes, campus life can be a very good life, and love of alma mater can lead to lifelong commitment to the institution. Lucius Sanford, executive director of the Letterwinner Association at Georgia Tech, is an example of the many college faculty members and employees who are homegrown, and who eventually return to campus and find a way to stay put. March 25, 2026 Atlanta Journal-Constitution Adam Van Brimmer reports, maritime trade is crawling at Georgia's ports, but the state authority that operates the nation's third-busiest cargo terminals isn't throttling back its expansion efforts. Container traffic is flat while wheeled and tracked cargo, such as autos, has experienced a double-digit decline for the fiscal year through February, Ports Authority CEO Griff Lynch told his board of directors Tuesday. March 25, 2026 Georgia Ports Authority Staff reports, the Georgia Ports Authority's new inland port in Gainesville, Ga., opens May 4, 2026, a development GPA says will strengthen Northeast Georgia's attractiveness and business competitiveness. With a direct connection to Savannah's 40 ships per week global ocean carrier network, local manufacturers - including poultry, heavy equipment, and forest product companies - can reach international markets more efficiently. March 25, 2026 Augusta Chronicle Erica Van Buren reports, as Georgia and South Carolina plunge into wildfire season, as recently evidenced by a wildfire in McCormick County this month, leftovers from Hurricane Helene might potentially feed some of the blazes. Hurricane Helene debris remains a concern in parts of Georgia and South Carolina, blocking access for firefighters and hindering wildfire suppression. March 25, 2025 The Brunswick News Taylor Cooper reports, the board of the Brunswick Housing Authority heard a proposal from an affordable housing developer Monday but declined to take action. Board members were interested but wanted more information. March 25, 2026 Columbus Ledger-Enquirer Mark Rice reports, six weeks after a proposed hyperscale data center in northeast Muscogee County was announced by Choose Columbus, the Columbus Consolidated Government hosted an information session in the Psalmond Road Recreation Center to highlight "the benefits", but many residents didn't get answers they sought. March 25, 2026 Milledgeville Union-Recorder Billy Hobbs reports, officials with The Development Authority of Milledgeville-Baldwin County agreed to a Memorandum of Understanding (MOU) on Monday morning with Grenergy USA for the construction of a new solar project. Beaver Creek Solar is slated to be built in the Coopers area of Baldwin County. March 25, 2026 Georgia Recorder Maya Homan reports, sixty miles away at the state Capitol in Atlanta, lawmakers are mulling a proposal to overhaul Georgia's election system ahead of the 2028 presidential election. But in a ballroom in Athens, hundreds of election workers charged with implementing the laws passed by the General Assembly are preparing to uphold Georgia's election laws, whatever those laws may be. March 25, 2026 Georgia Press Zoe Seiler reports that the Georgia General Assembly is considering legislation that would significantly reduce property taxes and create a new local homestead option sales tax to go toward property tax relief. The House advanced House Bill 1116, known as the Homeownership Opportunity and Market Equalization Act of 2026, on Crossover Day, March 6. March 25, 2026 State Affairs Beau Evans reports that a major bill to help children learn how to read is facing sharp scrutiny in the Senate with days left before the 2026 legislative session ends. Backers of the literacy measure have hailed it as a game changer for Georgia schools that have seen years of low scores for third grade students, with key aspects of the proposal centered on hiring more than 1,300 hands-on coaches to work with students and teachers on reading skills. March 25, 2026 Capitol Beat News Ty Tagami reports that a state-funded college scholarship based on financial need rather than academic merit took another step toward becoming a reality in Georgia on Tuesday when a Senate committee approved the bipartisan measure. House Bill 1413 passed the Senate Higher Education Committee unanimously after three other bills were merged with it. March 25, 2026 Atlanta Journal-Constitution Greg Bluestein, Tia Mitchell, Patricia Murphy and Adam Beam report, with airport security lines stretching for hours and the congressional stalemate over Homeland Security funding now in its sixth week, Atlanta's Delta Air Lines is suspending major travel perks for members of Congress. "Due to the impact on resources from the longstanding government shutdown, Delta will temporarily suspend specialty services to members of Congress flying Delta," a Delta statement read.
UCB to invest $2 billion in Georgia, establish first U.S. Manufacturing facility. Wednesday, March 25th, 2026 Governor Brian P. Kemp today announced that global biopharmaceutical giant UCB, Inc. is planning a significant investment of $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation's state-of-the-art, 2,000-acre science and learning campus in Gwinnett County. "When we met with UCB leadership earlier this year in Belgium, we discussed how the Peach State would be the right partner for their visionary plans in the U.S. that will benefit both patients and hardworking Georgians," said Governor Brian Kemp. "UCB's announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field." A global biopharmaceutical company based in Belgium, UCB's North American headquarters are located in Smyrna and currently support more than 400 jobs. UCB's expertise spans neurology and immunology. "This decision reflects our confidence in UCB's long-term growth and our deep-rooted commitment to the United States," said Jean-Christophe Tellier, CEO of UCB. "By investing in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities." UCB's new manufacturing footprint will be located at Rowen, serving as an anchor tenant for this 2,000-acre planned community in metro Atlanta designed to foster collaboration, knowledge sharing, and innovation. The cutting-edge campus will use a digital-first approach by leveraging AI, robotics, and automation while also prioritizing efficiency in the use of any natural resources. "We are thrilled that UCB has chosen Gwinnett County to advance its global operations and pioneering innovations," said Chairwoman Nicole Love Hendrickson, Gwinnett County Board of Commissioners. "An investment of this magnitude was exactly what we envisioned when we committed to establishing Rowen as a hub for collaboration and discovery. As one of the most dynamic and diverse counties in the nation, Gwinnett connects UCB to a highly skilled, globally connected talent pool. UCB's decision to invest here makes clear what industry leaders increasingly recognize: Gwinnett County is a partner in progress, committed to world-class infrastructure, premier services, and quality of life that support continued growth and success." "UCB's decision to locate their new manufacturing operation in Gwinnett County is a testament to the strength of our entire region to support the growth of the life sciences industry," said Katie Kirkpatrick, President and CEO of the Metro Atlanta Chamber. "UCB's innovation, talent, and strategic investment show that metro Atlanta is not just a hub for life sciences today, but a place where the breakthroughs of tomorrow are taking shape." Project Director EJane Caraway represented the Georgia Department of Economic Development's (GDEcD) Global Commerce team on this competitive project in partnership with Partnership Gwinnett, Metro Atlanta Chamber, Georgia Quick Start, and Georgia Power. "For more than a century, UCB has been a leader in biopharmaceutical innovation," said GDEcD Commissioner Pat Wilson. "Georgia's growing life sciences ecosystem and collaborative approach to economic development connect companies with world-class partners in research, education, logistics, and infrastructure. Together with our focus on being the Top State for Talent, it's why innovators like UCB choose Georgia to advance discoveries from R&D to real-world impact."